ERBB2 and glioblastoma: These data strongly support that the co-treatment of EGFRvIII-DBTE and HER2-DBTE result in improved efficacy in controlling heterogeneous GBM tumors through reduced heterogeneous tumor escape and illustrate the non-competitive nature of this combination approach.